Abbott Diabetes care

Name

Abbott Diabetes care

Legal name

Abbott Laboratories

Website

https://diabetescare.abbott

Company type

Public

Founded year

1888

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Continuous Glucose Monitoring

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)

akta.pro secondary industries

Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL), Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE), Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)

Keywords

• Continuous glucose monitoring
• Glucose monitoring systems
• Diabetes care devices
• CGM sensors
• Glucose tracking apps

Headquarters

HQ city

Alameda

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. CGM Sensor Sales: Abbott generates primary revenue through the sale of disposable CGM sensors that require replacement every 10-15 days. The recurring sensor purchase model creates a subscription-like revenue stream from the installed user base of 7 million worldwide users.
2. Reader and Reader Accessories: Sale of FreeStyle Libre reader devices and compatible accessories for users who prefer dedicated hardware over smartphone apps.
3. Software and Cloud Services: Revenue from LibreView cloud-based software platform and LibreLinkUp companion app services that support the CGM ecosystem.
4. Technology Licensing: Licensing of FreeStyle Libre CGM technology to insulin pump manufacturers for integration with automated insulin delivery systems, including Medtronic partnership estimated to add $100+ million in annual growth.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Abbott Diabetes Care designs, manufactures, and sells the FreeStyle Libre portfolio of factory-calibrated continuous glucose monitoring (CGM) sensor systems and readers, along with the LibreView cloud software, LibreLinkUp and FreeStyle LibreLink mobile apps. The CGM sensors are worn for 10–15 days and transmit real-time minute-by-minute glucose readings via Bluetooth to smartphones or dedicated readers, eliminating routine finger pricks. The portfolio also includes specialized sensors (Instinct, Instinct Go) for Medtronic pump integration, the Libre Rio over-the-counter CGM, the Lingo consumer wellness system, and traditional blood glucose monitors.

Product overview

Abbott Diabetes Care offers the FreeStyle Libre portfolio, a comprehensive continuous glucose monitoring (CGM) system portfolio led by FreeStyle Libre 3 as the flagship product. The portfolio includes multiple CGM sensor generations (FreeStyle Libre 3 Plus, FreeStyle Libre 2 Plus, FreeStyle Libre Select, FreeStyle Libre 2, and original FreeStyle Libre), supported by mobile applications (Libre App, FreeStyle LibreLink, LibreLinkUp) and cloud-based data management software (LibreView). The company also provides specialized sensors for insulin pump integration (Instinct, Instinct Go) through partnerships with Medtronic, Omnipod, Tandem, and others, as well as traditional blood glucose monitoring systems and the over-the-counter Libre Rio system. The ecosystem is designed for flexible glucose monitoring with real-time readings, automated insulin delivery integration, and connected health features.

Differentiator

Problem solved

Functional benefit

Brands

• FreeStyle Libre: World-leading continuous glucose monitoring portfolio including FreeStyle Libre, FreeStyle Libre 2, FreeStyle Libre 3, FreeStyle Libre 3 Plus, FreeStyle Libre Select, and Libre Rio systems.
• Lingo
• Instinct
• LibreView
• LibreLinkUp

Products and services

• FreeStyle Libre 3 System Continuous glucose monitoring system delivering 14-15 days of factory-calibrated, real-time minute-by-minute glucose readings via Bluetooth, the smallest and thinnest sensor in the FreeStyle Libre portfolio, with proven A1c reduction and hypoglycemia reduction.
• FreeStyle Libre 3 Plus Sensor CGM sensor variant authorized for integration with major automated insulin delivery systems, including mylife Loop (CamAPS FX, YpsoPump), Omnipod 5, Tandem t:slim X2, Beta Bionics iLet, and Tidepool twiist.
• FreeStyle Libre 2 System Continuous glucose monitoring system proven to help reduce hypoglycemia, with up to 15 days of wear, optional real-time alarms, and excellent accuracy in the low glucose range.
• FreeStyle Libre 2 Plus Sensor CGM sensor variant authorized for use with Omnipod 5 Automated Insulin Delivery System and Tandem t:slim X2 insulin pump.
• FreeStyle Libre Select System 15-day wear CGM sensor system that moves with users through showers, swimming, and exercise, with accurate glucose readings sent to an app or reader every minute.
• FreeStyle Libre System Original flash glucose monitoring system requiring no finger pricks, with a 1-second scan to view CGM data; water-resistant and wearable for up to 14 days.
• Libre App Companion mobile app for the FreeStyle Libre family of sensors featuring automatic glucose updates every minute and an enhanced alerts experience with escalating alarms and silent mode.
• FreeStyle LibreLink App Mobile app for FreeStyle Libre sensor users that displays glucose data and is compatible with NovoPen 6 and NovoPen Echo Plus smart insulin pens.
• LibreView Cloud-based software for glucose data management, integrated with FreeStyle Libre systems for viewing and sharing glucose data with healthcare providers.
• LibreLinkUp App Companion mobile app allowing users to share glucose insights with caregivers and family members, with compatibility for Omnipod 5 cloud connection.
• Libre Rio Continuous Glucose Monitoring System Non-intensive, over-the-counter integrated CGM device FDA-cleared in June 2024 for non-intensive glucose management without a prescription.
• Lingo Glucose Monitoring System Consumer-focused glucose monitoring system available in the U.S. for general wellness and health tracking.
• Instinct Sensor FreeStyle Libre-family sensor authorized for use with the Medtronic MiniMed 780G insulin pump and MiniMed Go Smart MDI app for automated insulin delivery.
• Instinct Go Sensor Sensor variant authorized for use with the MiniMed Go Smart MDI app, designed for simplified insulin delivery management.
• Blood Glucose Monitoring (BGM) Systems Traditional blood glucose monitors including FreeStyle Precision Neo, FreeStyle Lite, and FreeStyle Freedom Lite, which store insulin doses and glucose readings from finger-prick capillary blood samples.

Quantifiable outcome

• Trusted by 7 million users worldwide compared to other leading personal use sensor-based glucose monitoring systems
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration10 records

Feature5 records

Partnerships

Five partnerships are on record, tiered flagship and core.

• MedtronicflagshipTechnology or Integration · 7 August 2024Global partnership integrating Abbott's FreeStyle Libre CGM sensors with Medtronic's automated insulin delivery (AID) systems and smart insulin pens. Bank of America analysts estimate the deal could add over $100 million in annual growth to Abbott's Libre franchise and open a $700-850 million CGM market opportunity. Partnership gives Abbott access to Medtronic's 700,000 global insulin pump users, including 300,000 in the U.S.
• mylife Diabetes CarecoreTechnology or IntegrationFreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors authorized for use with mylife Loop automated insulin delivery system, including mylife CamAPS FX app and mylife YpsoPump insulin pump. Available in multiple European countries including France, Germany, Italy, Netherlands, Spain, UK.
• Insulet CorporationcoreTechnology or IntegrationFreeStyle Libre 3 Plus and FreeStyle Libre 2 Plus sensors authorized for use with Omnipod 5 Automated Insulin Delivery System. Available in 16 countries including Australia, Belgium, Denmark, France, Israel, Italy, Kuwait, Netherlands, Norway, Saudi Arabia, Sweden, UAE, UK, and USA.
• Tandem Diabetes CarecoreTechnology or IntegrationFreeStyle Libre 3 Plus sensor authorized for use with Tandem t:slim X2 insulin pump. Available in Finland, Italy, Sweden, Switzerland, USA, and New Zealand.
• Novo NordiskcoreTechnology or IntegrationFreeStyle LibreLink app compatible with NovoPen 6 and NovoPen Echo Plus smart insulin pens, enabling integration of glucose data with insulin dosing information. Available in 24 countries including major markets in Europe, Australia, Canada, and Japan.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Roche Diabetes Care: Roche is a broad incumbent in the blood glucose monitoring market (Accu-Chek) and a CGM participant, serving a similar diabetes patient base through pharmacy and prescription channels globally.
• LifeScan (Johnson & Johnson): LifeScan, formerly J&J's diabetes care unit, makes OneTouch blood glucose monitoring systems and is a peer in the BGM category, now under Platinum Equity ownership but competing in the same glucose monitoring channel.

Emerging players

• Senseonics Holdings: Senseonics manufactures Eversense, an implantable long-term CGM with 180-day and 365-day sensor wear, offering a differentiated alternative to Abbott's 14-15 day disposable sensors in the same glucose monitoring category.
• Tandem Diabetes Care: Tandem (t:slim X2) is an AID partner that integrates FreeStyle Libre 3 Plus sensors. Operates in the same insulin delivery + CGM ecosystem with overlapping Type 1 diabetes customer base.
• Insulet Corporation: Insulet (Omnipod 5) is both an AID partner integrating FreeStyle Libre 3 Plus sensors and a peer in the connected diabetes device ecosystem. Comparable through its tubeless patch pump technology and overlapping patient population with CGM users.
• Beta Bionics: Beta Bionics (iLet Bionics Pancreas) is an AID partner that integrates FreeStyle Libre 3 Plus sensors, operating in the same closed-loop insulin delivery ecosystem with overlapping Type 1 diabetes patient base.
• Ypsomed: Ypsomed (mylife Diabetes Care) is both an AID integration partner (mylife Loop with YpsoPump and CamAPS FX) and a peer in the connected diabetes device ecosystem, with overlapping CGM and pump customer base in Europe.

Direct peers

• Medtronic: Medtronic competes directly in CGM with its Guardian Connect system and is simultaneously Abbott's largest AID integration partner (MiniMed 780G uses Instinct/Abbott sensors). Comparable as a medtech peer across the diabetes care value chain.
• Ascensia Diabetes Care: Ascensia (formerly Bayer Diabetes Care) provides Contour blood glucose monitoring systems and is a peer in the BGM category that Abbott also serves with its FreeStyle Precision/Lite/Freedom Lite lines.
• Dexcom: Dexcom is the primary direct competitor to Abbott's FreeStyle Libre in the CGM market, with G7 and Stelo (OTC) sensor systems. Both companies compete head-to-head in continuous glucose monitoring for Type 1 and Type 2 diabetes with similar factory-calibrated, smartphone-connected sensors.

Market position

Weaknesses5 records

Competitive moat6 records

Key highlights7 records

Customer concentration

• Xx.com/FreeStyleDiabet
• YouTubeyoutube.com/channel/UCuWqQgITqBy-9XszhxLdKxQ
• Facebookfacebook.com/AbbottFreeStyle
• LinkedInlinkedin.com/company/abbott
• Instagraminstagram.com/freestylediabetes

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abbott Diabetes care